Learning objectives

After attending this webinar, learners will be able to:

• Describe novel therapeutic targets in GvHD and explain the mechanisms of action for new agents.
• Recall the latest data for new agents in development for GvHD and describe the rationale for selecting such treatments based on treatment- and patient-related factors.
• Explain how quality of life can be impacted in patients with GvHD and how this can be better managed in clinical practice.